Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin

[1]  N. Hensel,et al.  Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Florek,et al.  Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection , 1999, Bone Marrow Transplantation.

[3]  Dearden,et al.  The incidence and significance of fevers during treatment with antithymocyte globulin for aplastic anaemia , 1998, British journal of haematology.

[4]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Wuu,et al.  Lymphohematopoietic engraftment in minimally myeloablated hosts. , 1998, Blood.

[6]  C. Perreault,et al.  Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs.-host disease. , 1998, Experimental hematology.

[7]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[8]  R. Colvin,et al.  Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. , 1997, Transplantation.

[9]  N. Schmitz,et al.  German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem cells , 1997, Bone Marrow Transplantation.

[10]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[11]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[12]  Y. Colson,et al.  Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. , 1996, Journal of immunology.

[13]  A. Nagler,et al.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. , 1996, Blood.

[14]  A. Donnenberg,et al.  Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies. , 1996, Bone marrow transplantation.

[15]  R. Miralbell,et al.  Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Y. Colson,et al.  A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. , 1995, Journal of immunology.

[17]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[18]  F. Frassoni,et al.  CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. , 1995, Bone marrow transplantation.

[19]  R Storb,et al.  Use of a water-soluble busulfan formulation--pharmacokinetic studies in a canine model. , 1995, Blood.

[20]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[21]  H. Arendrup,et al.  Cytomegalovirus infection rate among heart transplant patients in relation to the potency of antithymocyte immunoglobulin induction therapy. Copenhagen Heart Transplant Group. , 1994, Transplantation proceedings.

[22]  K. Sullivan,et al.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  B. Hendry,et al.  The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. , 1996, Clinical nephrology.